{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:01:22Z","timestamp":1790136082638,"version":"4.0.1"},"reference-count":56,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Union\u2019s Horizon 2020 research and innovation program","award":["952491-AmReSu"],"award-info":[{"award-number":["952491-AmReSu"]}]},{"name":"European Union\u2019s Horizon 2020 research and innovation program","award":["BO\/00286\/22\/5"],"award-info":[{"award-number":["BO\/00286\/22\/5"]}]},{"name":"European Union\u2019s Horizon 2020 research and innovation program","award":["0272"],"award-info":[{"award-number":["0272"]}]},{"DOI":"10.13039\/501100003825","name":"J\u00e1nos Bolyai Research Scholarship of the Hungarian Academy of Sciences","doi-asserted-by":"publisher","award":["952491-AmReSu"],"award-info":[{"award-number":["952491-AmReSu"]}],"id":[{"id":"10.13039\/501100003825","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003825","name":"J\u00e1nos Bolyai Research Scholarship of the Hungarian Academy of Sciences","doi-asserted-by":"publisher","award":["BO\/00286\/22\/5"],"award-info":[{"award-number":["BO\/00286\/22\/5"]}],"id":[{"id":"10.13039\/501100003825","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003825","name":"J\u00e1nos Bolyai Research Scholarship of the Hungarian Academy of Sciences","doi-asserted-by":"publisher","award":["0272"],"award-info":[{"award-number":["0272"]}],"id":[{"id":"10.13039\/501100003825","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Semmelweis University-E\u00f6tv\u00f6s L\u00f3r\u00e1nd Research Network, Human Microbiota Study Group","award":["952491-AmReSu"],"award-info":[{"award-number":["952491-AmReSu"]}]},{"name":"Semmelweis University-E\u00f6tv\u00f6s L\u00f3r\u00e1nd Research Network, Human Microbiota Study Group","award":["BO\/00286\/22\/5"],"award-info":[{"award-number":["BO\/00286\/22\/5"]}]},{"name":"Semmelweis University-E\u00f6tv\u00f6s L\u00f3r\u00e1nd Research Network, Human Microbiota Study Group","award":["0272"],"award-info":[{"award-number":["0272"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>Delafloxacin is a novel fluoroquinolone agent that is approved for clinical application. In this study, we analyzed the antibacterial efficacy of delafloxacin in a collection of 47 Escherichia coli strains. Antimicrobial susceptibility testing was performed by the broth microdilution method and minimum inhibitory concentration (MIC) values were determined for delafloxacin, ciprofloxacin, levofloxacin, moxifloxacin, ceftazidime, cefotaxime, and imipenem. Two multidrug-resistant E. coli strains, which exhibited delafloxacin and ciprofloxacin resistance as well as extended-spectrum beta-lactamase (ESBL) phenotype, were selected for whole-genome sequencing (WGS). In our study, delafloxacin and ciprofloxacin resistance rates were 47% (22\/47) and 51% (24\/47), respectively. In the strain collection, 46 E. coli were associated with ESBL production. The MIC50 value for delafloxacin was 0.125 mg\/L, while all other fluoroquinolones had an MIC50 value of 0.25 mg\/L in our collection. Delafloxacin susceptibility was detected in 20 ESBL positive and ciprofloxacin resistant E. coli strains; by contrast, E. coli strains that exhibited a ciprofloxacin MIC value above 1 mg\/L were delafloxacin-resistant. WGS analysis on the two selected E. coli strains (920\/1 and 951\/2) demonstrated that delafloxacin resistance is mediated by multiple chromosomal mutations, namely, five mutations in E. coli 920\/1 (gyrA S83L, D87N, parC S80I, E84V, and parE I529L) and four mutations in E. coli 951\/2 (gyrA S83L, D87N, parC S80I, and E84V). Both strains carried an ESBL gene, blaCTX-M-1 in E. coli 920\/1 and blaCTX-M-15 in E. coli 951\/2. Based on multilocus sequence typing, both strains belong to the E. coli sequence type 43 (ST43). In this paper, we report a remarkable high rate (47%) of delafloxacin resistance among multidrug-resistant E. coli as well as the E. coli ST43 international high-risk clone in Hungary.<\/jats:p>","DOI":"10.3390\/microorganisms11061602","type":"journal-article","created":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T01:59:51Z","timestamp":1687139991000},"page":"1602","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Investigation of Delafloxacin Resistance in Multidrug-Resistant Escherichia coli Strains and the Detection of E. coli ST43 International High-Risk Clone"],"prefix":"10.3390","volume":"11","author":[{"given":"D\u00e1niel","family":"Guly\u00e1s","sequence":"first","affiliation":[{"name":"Institute of Medical Microbiology, Semmelweis University, 1089 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Kamotsay","sequence":"additional","affiliation":[{"name":"Central Microbiology Laboratory, National Institute of Hematology and Infectious Disease, Central Hospital of Southern-Pest, 1097 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00f3ra","family":"Szab\u00f3","sequence":"additional","affiliation":[{"name":"Institute of Medical Microbiology, Semmelweis University, 1089 Budapest, Hungary"},{"name":"Human Microbiota Study Group, Semmelweis University-E\u00f6tv\u00f6s L\u00f3r\u00e1nd Research Network, 1089 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7067-7055","authenticated-orcid":false,"given":"B\u00e9la","family":"Kocsis","sequence":"additional","affiliation":[{"name":"Institute of Medical Microbiology, Semmelweis University, 1089 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"dlac016","DOI":"10.1093\/jacamr\/dlac016","article-title":"Antibiotic resistance: Calling time on the \u2018silent pandemic\u2019","volume":"4","author":"Mendelson","year":"2022","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.jiph.2023.02.021","article-title":"A parallel and silent emerging pandemic: Antimicrobial resistance (AMR) amid COVID-19 pandemic","volume":"16","author":"Rehman","year":"2023","journal-title":"J. Infect. Public. Health"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"i5","DOI":"10.1093\/jacamr\/dlab052","article-title":"Antibiotic resistance during and beyond COVID-19","volume":"3","author":"Livermore","year":"2021","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_4","unstructured":"Antimicrobial Resistance Collaborators (2022). Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet, 399, 629\u2013655."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Thompson, T. (Nature, 2022). The staggering death toll of drug-resistant bacteria, Nature, epub ahead of print.","DOI":"10.1038\/d41586-022-00228-x"},{"key":"ref_6","unstructured":"O\u2019Neill, J. (2014). Review on Antimicrobial Resistance. Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations, Wellcome Trust. Available online: https:\/\/amr-review.org\/Publications.html."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13756-019-0590-7","article-title":"Economic burden of antibiotic resistance in ESKAPE organisms: A systematic review","volume":"8","author":"Zhen","year":"2019","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1556\/030.2022.01640","article-title":"Changes in resistance pattern of ESKAPE pathogens between 2010 and 2020 in the clinical center of University of Szeged, Hungary","volume":"69","author":"Orosz","year":"2022","journal-title":"Acta Microbiol. Immunol. Hung."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41429-020-0291-8","article-title":"Antibiotics in the clinical pipeline in October 2019","volume":"73","author":"Butler","year":"2020","journal-title":"J. Antibiot."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s40265-021-01580-4","article-title":"Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"key":"ref_12","first-page":"704","article-title":"Plazomicin: A new aminoglycoside","volume":"70","author":"Saravolatz","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41579-019-0159-8","article-title":"Interplay between beta-lactamases and new beta-lactamase inhibitors","volume":"17","author":"Bush","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Kocsis, B., Guly\u00e1s, D., and Szab\u00f3, D. (2021). Delafloxacin, Finafloxacin, and Zabofloxacin: Novel Fluoroquinolones in the Antibiotic Pipeline. Antibiotics, 10.","DOI":"10.3390\/antibiotics10121506"},{"key":"ref_15","unstructured":"(2021, August 20). Dong Wha Pharm\u2019s Quinolone Antibacterial Agent, \u201cZabolante\u201d, Wins at the 19th KNDA (Press Release 28 February 2018). Available online: https:\/\/www.dong-wha.co.kr\/english\/customer\/dnews\/content.asp?t_idx=1139."},{"key":"ref_16","unstructured":"U.S. Food and Drug Administration (2018, December 08). BAXDELA (Delafloxacin) Prescribing Information and Medication Guide, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208610s000,208611s000lbl.pdf."},{"key":"ref_17","unstructured":"U.S. Food and Drug Administration (2021, August 20). XTORO Prescribing Information and Medication Guide 2014, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206307s000lbl.pdf."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12941-016-0150-4","article-title":"Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin","volume":"15","author":"Kocsis","year":"2016","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Rusu, A., Lungu, I.A., Moldovan, O.L., Tanase, C., and Hancu, G. (2021). Structural Characterization of the Millennial Antibacterial (Fluoro)Quinolones-Shaping the Fifth Generation. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13081289"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Lungu, I.A., Moldovan, O.L., Biri\u0219, V., and Rusu, A. (2022). Fluoroquinolones Hybrid Molecules as Promising Antibacterial Agents in the Fight against Antibacterial Resistance. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14081749"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Rusu, A., Munteanu, A.C., Arb\u0103na\u0219i, E.M., and Uivarosi, V. (2023). Overview of Side-Effects of Antibacterial Fluoroquinolones: New Drugs versus Old Drugs, a Step Forward in the Safety Profile?. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15030804"},{"key":"ref_22","unstructured":"European Medicines Agency (EMA) (2018, December 08). Quinolone- and Fluoroquinolone-Containing Medicinal Products: Disabling and Potentially Permanent Side Effects Lead to Suspension or Restrictions of Quinolone and Fluoroquinolone Antibiotics. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/quinolone-fluoroquinolone-containing-medicinal-products."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/jac\/dkx543","article-title":"Clinical review of delafloxacin: A novel anionic fluoroquinolone","volume":"73","author":"Mogle","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s40261-020-00953-z","article-title":"Community-Acquired Bacterial Pneumonia-Changing Epidemiology, Resistance Patterns, and Newer Antibiotics: Spotlight on Delafloxacin","volume":"40","author":"Sharma","year":"2020","journal-title":"Clin. Drug Investig."},{"key":"ref_25","unstructured":"European Medicines Agency (2020, March 16). Quofenix (Delafloxacin): Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s40265-020-01358-0","article-title":"Delafloxacin: A review in acute bacterial skin and skin structure infections","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"ref_27","unstructured":"Melinta Therapeutics (2020, March 16). Baxdela (Delafloxacin) Tablets, for Oral Use; Baxdela (Delafloxacin) for Injection, for Intravenous Use: U.S. Prescribing Information. Available online: https:\/\/baxdela.com\/docs\/baxdela-prescribing-information.pdf."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/nyas.12830","article-title":"Mechanisms of drug resistance: Quinolone resistance","volume":"1354","author":"Hooper","year":"2015","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1128\/AAC.38.10.2477","article-title":"Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs","volume":"38","author":"Vila","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.drup.2016.09.001","article-title":"Plasmid-mediated quinolone resistance: Two decades on","volume":"29","author":"Machuca","year":"2016","journal-title":"Drug Resist. Update"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1089\/mdr.2018.0245","article-title":"Ciprofloxacin Promoted qnrD Expression and Phylogenetic Analysis of qnrD Harboring Plasmids","volume":"25","author":"Kocsis","year":"2019","journal-title":"Microb. Drug Resist."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e02555-16","DOI":"10.1128\/AAC.02555-16","article-title":"qnrE1, a Member of a New Family of Plasmid-Located Quinolone Resistance Genes, Originated from the Chromosome of Enterobacter Species","volume":"61","author":"Albornoz","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e0045621","DOI":"10.1128\/AAC.00456-21","article-title":"Identification of qnrE3 and qnrE4, New Transferable Quinolone Resistance qnrE Family Genes Originating from Enterobacter mori and Enterobacter asburiae, Respectively","volume":"65","author":"Wang","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"N\u00fa\u00f1ez-Samudio, V., Pecchio, M., Pimentel-Peralta, G., Quintero, Y., Herrera, M., and Landires, I. (2021). Molecular Epidemiology of Escherichia coli Clinical Isolates from Central Panama. Antibiotics, 10.","DOI":"10.3390\/antibiotics10080899"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1099\/mic.0.000063","article-title":"Guide to the various phylogenetic classification schemes for Escherichia coli and the correspondence among schemes","volume":"161","author":"Clermont","year":"2015","journal-title":"Microbiology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1128\/JCM.03502-13","article-title":"Rapid and specific detection, molecular epidemiology, and experimental virulence of the O16 subgroup within Escherichia coli sequence type 131","volume":"52","author":"Johnson","year":"2014","journal-title":"J. Clin. Microbiol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Kocsis, B., Guly\u00e1s, D., and Szab\u00f3, D. (2022). Emergence and Dissemination of Extraintestinal Pathogenic High-Risk International Clones of Escherichia coli. Life, 12.","DOI":"10.3390\/life12122077"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12688\/f1000research.10609.1","article-title":"Escherichia coli ST131: A multidrug-resistant clone primed for global domination","volume":"6","author":"Pitout","year":"2017","journal-title":"F1000Res"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1556\/030.2022.01826","article-title":"Distribution and expression of virulence genes (hlyA, sat) and genotyping of Escherichia coli O25b\/ST131 by multi-locus variable number tandem repeat analysis in Tehran, Iran","volume":"69","author":"Asgharzadeh","year":"2022","journal-title":"Acta Microbiol. Immunol. Hung."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1089\/mdr.2013.0152","article-title":"KPC-3 carbapenemase harbored in FIIk plasmid from Klebsiella pneumoniae ST512 and Escherichia coli ST43 in the same patient","volume":"20","author":"Kocsis","year":"2014","journal-title":"Microb. Drug Resist."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jgar.2013.07.003","article-title":"Infections caused by fluoroquinolone-resistant Escherichia coli following transrectal ultrasound-guided biopsy of the prostate","volume":"2","author":"Suwantarat","year":"2014","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e0055021","DOI":"10.1128\/mSphere.00550-21","article-title":"Arrangements of Mobile Genetic Elements among Virotype E Subpopulation of Escherichia coli Sequence Type 131 Strains with High Antimicrobial Resistance and Virulence Gene Content","volume":"6","author":"Pajand","year":"2021","journal-title":"mSphere"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Massella, E., Giacometti, F., Bonilauri, P., Reid, C., Djordjevic, S., Merialdi, G., Bacci, C., Fiorentini, L., Massi, P., and Bardasi, L. (2021). Antimicrobial Resistance Profile and ExPEC Virulence Potential in Commensal Escherichia coli of Multiple Sources. Antibiotics, 10.","DOI":"10.3390\/antibiotics10040351"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12941-022-00493-8","article-title":"Population snapshot of the extended-spectrum \u03b2-lactamase-producing Escherichia coli invasive strains isolated from a Hungarian hospital","volume":"21","author":"Kamotsay","year":"2022","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1556\/030.62.2015.3.2","article-title":"Identification and characterization of CTX-M-15 producing Klebsiella pneumoniae clone ST101 in a Hungarian university teaching hospital","volume":"62","author":"Melegh","year":"2015","journal-title":"Acta Microbiol. Immunol. Hung."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1099\/jmm.0.050542-0","article-title":"Identification of blaLAP-2 and qnrS1 genes in the internationally successful Klebsiella pneumoniae ST147 clone","volume":"62","author":"Kocsis","year":"2013","journal-title":"J. Med. Microbiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3389\/fmicb.2019.00157","article-title":"Multiple Benefits of Plasmid-Mediated Quinolone Resistance Determinants in Klebsiella pneumoniae ST11 High-Risk Clone and Recently Emerging ST307 Clone","volume":"10","author":"Domokos","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Horv\u00e1th, M., Kov\u00e1cs, T., Kun, J., Gyenesei, A., Damjanova, I., Tigyi, Z., and Schneider, G. (2023). Virulence Characteristics and Molecular Typing of Carbapenem-Resistant ST15 Klebsiella pneumoniae Clinical Isolates, Possessing the K24 Capsular Type. Antibiotics, 12.","DOI":"10.3390\/antibiotics12030479"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Muraya, A., Kyany\u2019a, C., Kiyaga, S., Smith, H.J., Kibet, C., Martin, M.J., Kimani, J., and Musila, L. (2022). Antimicrobial Resistance and Virulence Characteristics of Klebsiella pneumoniae Isolates in Kenya by Whole-Genome Sequencing. Pathogens., 11.","DOI":"10.1101\/2022.02.01.478614"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/femsre\/fux013","article-title":"Klebsiella pneumoniae: A major worldwide source and shuttle for antibiotic resistance","volume":"41","author":"Kondratyeva","year":"2017","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s10096-013-2022-6","article-title":"Fitness cost associated with resistance to fluoroquinolones is diverse across clones of Klebsiella pneumoniae and may select for CTX-M-15 type extended-spectrum beta-lactamase","volume":"33","author":"Toth","year":"2014","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1093\/jac\/dku308","article-title":"Interplay between plasmid-mediated and chromosomal-mediated fluoroquinolone resistance and bacterial fitness in Escherichia coli","volume":"69","author":"Machuca","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.3389\/fmicb.2017.02261","article-title":"Double-Serine Fluoroquinolone Resistance Mutations Advance Major International Clones and Lineages of Various Multi-Drug Resistant Bacteria","volume":"8","author":"Fuzi","year":"2017","journal-title":"Front. Microbiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1128\/AAC.02798-15","article-title":"In Vitro Activity of Delafloxacin against Clinical Neisseria gonorrhoeae Isolates and Selection of Gonococcal Delafloxacin Resistance","volume":"60","author":"Soge","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"106795","DOI":"10.1016\/j.ijantimicag.2023.106795","article-title":"High-level delafloxacin resistance through the combination of two different mechanisms in Staphylococcus aureus","volume":"61","author":"Cisneros","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e0007921","DOI":"10.1128\/AAC.00079-21","article-title":"Comparison of In Vitro Susceptibility of Delafloxacin with Ciprofloxacin, Moxifloxacin, and Other Comparator Antimicrobials against Isolates of Nontuberculous Mycobacteria","volume":"65","author":"Wallace","year":"2021","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/11\/6\/1602\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:56:52Z","timestamp":1760126212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/11\/6\/1602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":56,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["microorganisms11061602"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms11061602","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,16]]}}}